Valuation: Verastem, Inc.

Market Cap 615M 532M 498M 455M 857M 58.65B 870M 5.83B 2.29B 29.34B 2.31B 2.26B 97.72B P/E 2026 *
-4.23x
P/E 2027 * -5.83x
Enterprise Value 657M 569M 531M 486M 915M 62.64B 930M 6.23B 2.45B 31.34B 2.47B 2.41B 104B EV / Sales 2026 *
5.64x
EV / Sales 2027 * 2.24x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.74%
1 week+19.33%
Current month+17.07%
1 month+22.78%
3 months+38.85%
6 months+8.12%
Current year-12.05%
1 week 5.73
Extreme 5.73
7.1
1 month 5.1
Extreme 5.1
7.1
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Sell

Chief Executive Officer

-1,302 0.0021%
5/21/26 Free

Chairman

36,000 0.0410%
5/21/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%+19.33%+0.74%-30.86% 615M
+4.21%+25.56%+77.96%+104.49% 70.85B
0.00%+5.38%+38.68%+68.73% 55.41B
+2.78%+36.87%+23.00%+493.09% 29.43B
-0.30%+13.64%+54.71%+6.07% 24.12B
-0.93%+0.60%-16.89%-12.00% 23.31B
+0.90%+6.82%+47.77%-21.30% 18.37B
+7.26%+14.16%+221.03%+393.89% 16.99B
0.00%+9.69%+31.01%+584.59% 16.1B
-2.05%-3.81%+40.40%+150.40% 13.12B
Average +1.31%+352.82%+51.84%+173.71% 26.83B
Weighted average by Cap. +1.77%+349.84%+55.65%+161.21%

Financials

2026 *2027 *
Net sales 116M 101M 94.22M 86.12M 162M 11.11B 165M 1.1B 434M 5.56B 437M 428M 18.5B 181M 157M 147M 134M 252M 17.27B 256M 1.72B 674M 8.64B 680M 665M 28.78B
Net income -166M -144M -134M -123M -231M -15.82B -235M -1.57B -618M -7.91B -623M -609M -26.36B -159M -137M -128M -117M -221M -15.13B -225M -1.51B -591M -7.57B -596M -583M -25.21B
Net Debt 41.9M 36.27M 33.9M 30.99M 58.39M 4B 59.31M 398M 156M 2B 157M 154M 6.66B -210M -181M -170M -155M -292M -19.99B -297M -1.99B -780M -10B -787M -770M -33.31B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-08-10 US$6.790 +0.74% 2,298,110
26-08-07 US$6.740 +14.04% 4,319,009
26-08-06 US$5.910 +0.68% 2,189,459
26-08-05 US$5.870 +1.03% 1,554,979
26-08-04 US$5.810 +2.11% 1,791,796
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.790USD
Average target price
14.75USD
Spread / Average Target
+117.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock